AstraZeneca, as part of its ongoing $3.5 billion investment in American innovation, opened its first U.S.-operated cell therapy factory in Maryland to help treat cancer patients. The U.K-based ...

AstraZeneca (AZN) CEO Pascal Soriot is not overly concerned about the threat of tariffs by the Trump administration on pharmaceuticals and said a more favorable corporate tax credit could motivate ...

AstraZeneca has shown its commitment to China amid investigations into its executives and activities, outlining plans to establish a global strategic R&D center in Beijing as part of a $2.5 ...

Eneboparatide hits primary endpoint in AstraZeneca’s Phase 3 trial for chronic hypoparathyroidism, showing significant efficacy at 24 weeks. The EU approved AstraZeneca’s Imfinzi for limited ...

British pharmaceutical giant AstraZeneca on Monday announced an agreement to buy Belgian cell therapy firm EsoBiotec for up to $1 billion, expanding its treatments for cancer. EsoBiotec's ...

U.K.-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) is making news, but not in a good way. Its operations in China were recently rocked when Leon Wang, the company's president in the country ...

AstraZeneca is facing some headwinds related to its operations in China. Still, the company's financial results and pipeline look strong. The stock could deliver solid returns for those who invest ...

AstraZeneca has refuted allegations its staff “refuse to cooperate and respect” the U.K. marketing code. The drugmaker successfully defended itself against claims senior staff ignored requests ...

AstraZeneca has appointed WPP as one of its primary oncology network partners. Under WPP’s new remit as a global creative partner, the agency will support U.S. and global advertising for AstraZeneca’s ...

AstraZeneca’s booming oncology business has won over cancer patient groups. Having languished down the leaderboard in the past, the drugmaker vaulted (PDF) over many rivals in PatientView’s ...

AstraZeneca's newly-announced ambitions point to big growth ahead. At the same time, Pfizer's strategy is also proving quite ambitious. AstraZeneca isn't planning on doing as much business ...

AstraZeneca is withdrawing its highly successful coronavirus vaccine, citing the availability of a plethora of new shots that has led to a decline in demand. The vaccine — called Vaxzevria and ...